Navigation Links
Postdiagnosis aspirin use reduces risk of dying from colorectal cancer
Date:8/11/2009

Regular use of aspirin after colorectal cancer diagnosis may reduce the risk of cancer death, report investigators from Massachusetts General Hospital (MGH), Dana-Farber Cancer Institute and Brigham and Women's Hospital. In the August 12 issue of the Journal of the American Medical Association, the study's authors also find that the aspirin-associated survival advantage was seen primarily in patients with tumors expressing the COX-2 enzyme, a characteristic of two-thirds of colorectal cancers.

"While previous studies by our group and others showed that aspirin and other non-steroidal anti-inflammatory drugs reduce the risk of developing colorectal cancer, this study is the among the first to show that aspirin can also improve survival in patients who have already been diagnosed with colorectal cancers. Moreover, the benefit appeared to be especially strong among patients with cancers that express COX-2," says Andrew Chan, MD, MPH, of the MGH Gastrointestinal Unit, the study's lead author. "This is an important first step toward developing targeted approaches to improving patient outcomes."

Many previous studies have shown that regular use of aspirin and other non-steroidal anti-inflammatory drugs reduces the risk of developing colorectal cancer. In 2007, the same MGH/DFCI research team found that the benefit only applied to tumors overexpressing COX-2, an enzyme believed to drive tumor growth and known to be inhibited by aspirin and related drugs. To test their hypotheses that aspirin would also improve the survival of patients diagnosed with colorectal cancer, again through its inhibition of COX-2, the researchers compiled data from two ongoing prospective research studies the Nurses Health Study (NHS) and the Health Professionals Follow-Up Study (HPFS). Both studies gather comprehensive health information on their participants every two years; data are then analyzed for associations between factors such as medication use and the incidence of several diseases.

The current study focused on 1,279 study participants who were diagnosed with stage 1, 2 or 3 colorectal cancer during their participation in the studies for whom data was available on aspirin use before and after diagnosis. Tumor samples available from 459 participants were analyzed for the expression of COX-2. Study results indicated that patients who regularly took aspirin after their diagnosis had a nearly 30 percent lower risk of dying of colorectal cancer during an average of 11 years after diagnosis than did non-aspirin users. The benefit was especially strong among patients who began using aspirin after diagnosis. In contrast, patients who were aspirin users before diagnosis did not appear to benefit as much from continuing aspirin use after diagnosis. As expected, the survival benefit appeared restricted to patients with COX-2-positive tumors.

"We believe our results could lead to improvements in the therapy of patient with colon cancer," says Charles Fuchs, MD, MPH, of Dana-Farber, the study's senior author. "We're now following up this observational study with a randomized trial to evaluate adding the COX-2 inhibitor celecoxib which is less likely to have the gastrointestinal side effects of aspirin to standard chemotherapy."


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Aspirin May Stem Deaths From Colorectal Cancer
2. Corgenix to Exhibit AspirinWorks(R) Test at 2009 ISTH Meeting
3. Drug Limits Stomach Trouble in Patients Taking Low-Dose Aspirin
4. Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others
5. Value of Taking Aspirin to Cut Heart Risk Varies
6. Chewable Aspirin More Readily Absorbed
7. Study compares formulations of 3 aspirin types
8. Study compares formulations of three aspirin types
9. Aspirin Lowers Stroke Risk in Peripheral Artery Disease
10. Aspirin Linked to Brain Microbleeds
11. Plavix Plus Aspirin Lowers Stroke Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of ... of excellence for the field of eating disorders, announces the opening of early ... in Orlando, Florida at the Omni Resort at ChampionsGate. , The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new ... at MIBio 2017 in Cambridge, U.K on ... in biopharmaceutical samples with unprecedented speed and sensitivity while using far ... Membrane Imaging. ... particle analysis system ...
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
Breaking Medicine Technology: